Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2955-2961

  Liu, Chun Jen ^a   Chen, Pei Jer ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dual infection; Hepatitis B surface antigen clearance; Hepatitis B virus; Hepatitis C virus; Interferon; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERLEUKIN 28; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA; ANTIVIRUS AGENT;

ARTICLE; DISEASE ASSOCIATION; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; MORTALITY; NONHUMAN; RISK ASSESSMENT; SEROLOGY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION; COINFECTION; COMPLICATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84896468762     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2955     Document Type: Article

References (37)

1. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005; 104: 783-791 [PMID: 16496056]
2. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817-822 [PMID: 2169497 DOI: 10.1093/infdis/162.4.817]
3. Liu CJ, Chen PJ, Shau WY, Kao JH, Lai MY, Chen DS. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int 2003; 23: 148-155 [PMID: 12955877 DOI: 10.1034/j.1600-0676.2003.00820.x]
4. D'Amelio R, Matricardi PM, Biselli R, Stroffolini T, Mele A, Spada E, Chionne P, Rapicetta M, Ferrigno L, Pasquini P. Changing epidemiology of hepatitis B in Italy: public health implications. Am J Epidemiol 1992; 135: 1012-1018 [PMID: 1595687]
5. Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodríguez M, San Miguel G, Artiñano E, Pons-Romero F. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994; 89: 1147-1151 [PMID: 8053425]
6. Treitinger A, Spada C, Ferreira LA, Neto MS, Reis M, Verdi JC, de Miranda AF, de Oliveira OV, Van der Sander Silveira M, Abdalla DS. Hepatitis B and hepatitis C prevalence among blood donors and HIV-1 infected patients in Florianópolis--Brazil. Braz J Infect Dis 2000; 4: 192-196 [PMID: 11008223]
7. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029 [PMID: 15057742 DOI: 10.1053/j.gastro.2004.01.011]
8. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-354 [PMID: 9455792]
9. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011; 29: 3643-3650 [PMID: 21859997 DOI: 10.1200/JCO.2011.36.2335]
10. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, Squadrito G, Tono N. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-107 [PMID: 16323213 DOI: 10.1002/hep.20944]
11. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504. e3 [PMID: 19084016 DOI: 10.1053/j.gastro.2008.10.049]
12. Uyanikoglu A, Akyuz F, Baran B, Simsek BP, Ermis F, Demir K, Gulluoglu M, Badur S, Kaymakoglu S. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013; 37: 485-490 [PMID: 23665172]
13. Kim YJ, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, Kim BH, Lee CK, Park CK, Park SH. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol 2011; 17: 199-205 [PMID: 22102386 DOI: 10.3350/kjhep.2011.17.3.199]
14. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49: 688-694 [PMID: 18490077 DOI: 10.1016/j.jhep.2008.03.028]
15. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 2013; 57: 2135-2142 [PMID: 23322699 DOI: 10.1002/hep.26266]
16. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 2009; 3: 517-525 [PMID: 19669238 DOI: 10.1007/s12072-009-9147-9]
17. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011; 54: 381-392 [PMID: 21721025]
18. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
19. Omata M, Kanda T, Yu ML, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435 [DOI: 10.1007/s12072-012-9342-y]
20. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-576 [PMID: 12601355 DOI: 10.1053/jhep.2003.50096]
21. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005; 20: 727-732 [PMID: 15853986 DOI: 10.1111/j.1440-1746.2005.03791.x]
22. Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005; 10: 125-133 [PMID: 15751770]
23. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601 [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]
24. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845]
25. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Stephen Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561 [DOI: 10.1007/s12072-012-9386-z]
26. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010; 202: 86-92 [PMID: 20482252 DOI: 10.1086/653209]
27. Gordon SC, Sherman KE. Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology 2009; 136: 393-396 [PMID: 19105960 DOI: 10.1053/j.gastro.2008.12.017]
28. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007; 297: 724-732 [PMID: 17312292 DOI: 10.1001/jama.297.7.724]
29. Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G, Sagnelli E. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat 2012; 19: 890-896 [PMID: 23121368 DOI: 10.1111/j.1365-2893.2012.01627.x]
30. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-994 [PMID: 17302368]
31. Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther 2011; 16: 959-968 [PMID: 22024511 DOI: 10.3851/IMP1842]
32. Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014; 63: 506-514 [PMID: 23676440 DOI: 10.1136/gutjnl-2012-304370]
33. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013; 8: e53008 [PMID: 23326374 DOI: 10.1371/journal.pone.0053008]
34. Cheng HR, Kao JH, Wu HL, Chen TC, Tseng TC, Liu CH, Su TH, Chen PJ, Chen DS, Liu CJ. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. Liver Int 2013; Epub ahead of print [PMID: 24119014 DOI: 10.1111/liv.12324.]
35. Hung CH, Chen CH, Lu SN, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. Antiviral Res 2012; 93: 55-63 [PMID: 22061616 DOI: 10.1016/j.antiviral.2011.10.018]
36. Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, Ahmed A, Lutchman GA, Keeffe EB, Nguyen MH. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011; 53: 1839-1845 [PMID: 21425314 DOI: 10.1002/hep.24308]
37. Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers. Neth J Med 2008; 66: 191-195 [PMID: 18490796]